154 related articles for article (PubMed ID: 37317905)
21. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
[TBL] [Abstract][Full Text] [Related]
22. Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Shi XB; Jiang JF; Jin FX; Cheng W
World J Clin Cases; 2019 May; 7(9):1087-1092. PubMed ID: 31123683
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of the clinical features of 172 patients with
Lin X; Huang H; Chen P
Mol Cytogenet; 2020; 13():8. PubMed ID: 32095159
[TBL] [Abstract][Full Text] [Related]
24. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
26. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
[TBL] [Abstract][Full Text] [Related]
27. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
28. [Chronic myeloid leukemia onset with marked thrombocythemia].
Shen Q; Zhou JW; Zhu GR; Yang YY; Qiu HR; Zhu GR; Xia W; Jiang PJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):247-51. PubMed ID: 16638190
[TBL] [Abstract][Full Text] [Related]
29. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
30. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
32. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
Li ZL; Gao L; Zhang H; Zhang CX; Chen YR; Huang FZ; Gong M; Gao YY; Tang Y; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1122-1128. PubMed ID: 30111418
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
Bisen A; Claxton DF
Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
[TBL] [Abstract][Full Text] [Related]
34. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
35. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
36. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
[TBL] [Abstract][Full Text] [Related]
37. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Kurzrock R; Kantarjian HM; Shtalrid M; Gutterman JU; Talpaz M
Blood; 1990 Jan; 75(2):445-52. PubMed ID: 2403827
[TBL] [Abstract][Full Text] [Related]
38. [Detection of BCR/ABL fusion gene by fluorescence in situ hybridization and its clinical application].
Zhou RL; Mo YX; Lan M; Lin JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1283-8. PubMed ID: 22040989
[TBL] [Abstract][Full Text] [Related]
39. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
40. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
